Advancing the Therapeutic Potential of Epitranscriptomics: Storm’s Firstin- Class METTL3 Inhibitor, STC-15
Time: 9:45 am
day: Conference Day Two
Details:
• Preclinical data demonstrates that modulating RNA methylation via METTL3 inhibition can enhance tumor sensitivity to treatment and impair resistance mechanisms
• Epitranscriptomic regulation produces durable changes to gene expression and the tumor microenvironment, suggesting anti-cancer efficacy through multiple mechanisms
• STC-15 clinical and translational data point to broad utility of METTL3 inhibition, enabling new treatment approaches across oncology indications
